KatsanosKSpiliopoulosSKitrouPet al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.
2.
HillAB.The environment and disease: association or causation?Proc R Soc Med. 1965;58:295-300.
3.
TallaridaRJJacobsLS. The Dose-Response Relation in Pharmacology. New York: Springer; 1979:1-17.
4.
HamadaNFujimichiY.Classification of radiation effects for dose limitation purposes: history, current situation and future prospects. J Radiat Res. 2014;55:629-640.
5.
LittleMP.Risks associated with ionizing radiation. Br Med Bull. 2003;68:259-275.
ShulmanLNBerryDACirrincioneCTet al. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014;32:2311-2317.
8.
MayerEL.Use of paclitaxel as a primary therapy in oncology: outcomes, benefits, adverse events and doses compared to devices. Paper presented at VIVA Vascular Leaders Forum (VLF); March 1-2, 2019; Washington DC, USA.
9.
PignataSScambiaGKatsarosDet al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014;15:396–405.
10.
FreyhardtPZellerTKrönckeTJet al. Plasma levels following application of paclitaxel-coated balloon catheter in patients with stenotic, or occluded femoro-popliteal arteries. Röfo. 2011;183:448-455.
11.
DakeMD.Long-term safety information on paclitaxel-eluting stents: insights from the Zilver PTX program. Paper presented at LINC 2019; January 22-25, 2019; Leipzig, Germany.
12.
SchneiderPALairdJRDorrosGet al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis. J Am Coll Cardiol. 2019;73(20):2550-2563.
13.
GrayWA. Patient safety in the Eluvia DES and Ranger DCB program. Abstract presented at LINC2019; January 22-25, 2019; Leipzig, Germany.
14.
LydenS. Long-term safety data from the Stellarex DCB program. Paper presented at LINC2019; January 22-25, 2019; Leipzig, Germany.
15.
AlbrechtTSchnorrBKutscheraMet al. Two-year mortality after angioplasty of the femoro-popliteal artery with uncoated balloons and paclitaxel-coated balloons-a pooled analysis of four randomized controlled multicenter trials. Cardiovasc Intervent Radiol. 2019Mar6. doi: 10.1007/s00270-019-02194-w.
16.
SchneiderPALairdJRTepeGet al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial. Circ Cardiovasc Interv. 2018;11:e005891.
17.
Laird JR. 5-Year results from the IN.PACT SFA randomized trial. Paper presented at VIVA 2018; November 5-8, 2018; Las Vegas, NV, USA.
18.
DakeMDAnselGMJaffMRet al; Zilver PTX Investigators. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133(15):1472-1483.
19.
RosenfieldKJaffMRWhiteCJet al; LEVANT 2 Investigators. Trial of apaclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373(2):145-153.
